Galectin Therapeutics Inc. - Common Stock (GALT)
4.0450
-0.0350 (-0.86%)
NASDAQ · Last Trade: Dec 30th, 12:06 PM EST
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Galectin Therapeutics Inc. (“Galectin” or “the Company”) (NASDAQ: GALT) for violations of the securities laws.
By The Schall Law Firm · Via Business Wire · December 29, 2025
Issued on behalf of Oncolytics Biotech Inc. Vancouver, BC – June 18, 2025 – USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer. In fact, the report cites a recent study from the National Institutes of Health (NIH), which found that between […]
Via FinancialNewsMedia · June 18, 2025